Michael Rothe

4.1k total citations
122 papers, 3.1k citations indexed

About

Michael Rothe is a scholar working on Biochemistry, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Michael Rothe has authored 122 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Biochemistry, 30 papers in Molecular Biology and 28 papers in Pathology and Forensic Medicine. Recurrent topics in Michael Rothe's work include Eicosanoids and Hypertension Pharmacology (39 papers), Alcohol Consumption and Health Effects (23 papers) and Fatty Acid Research and Health (18 papers). Michael Rothe is often cited by papers focused on Eicosanoids and Hypertension Pharmacology (39 papers), Alcohol Consumption and Health Effects (23 papers) and Fatty Acid Research and Health (18 papers). Michael Rothe collaborates with scholars based in Germany, United States and Spain. Michael Rothe's co-authors include Fritz Pragst, Wolf‐Hagen Schunck, Karsten H. Weylandt, Friedrich C. Luft, Dominik N. Müller, Robert Fischer, Anne Konkel, Ralf Dechend, Clemens von Schacky and Martin Hastedt and has published in prestigious journals such as Science, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Michael Rothe

118 papers receiving 3.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Rothe Germany 31 959 727 610 598 414 122 3.1k
Alberto Boveris Argentina 32 489 0.5× 2.9k 4.0× 545 0.9× 589 1.0× 185 0.4× 68 6.1k
Jean Chaudière France 22 298 0.3× 901 1.2× 734 1.2× 150 0.3× 157 0.4× 40 2.9k
Holger Steinbrenner Germany 34 174 0.2× 1.3k 1.8× 2.1k 3.5× 236 0.4× 164 0.4× 68 4.5k
Yoshiaki Hashimoto Japan 33 186 0.2× 1.7k 2.4× 158 0.3× 214 0.4× 357 0.9× 195 4.2k
Desirée Bartolini Italy 30 235 0.2× 1.0k 1.4× 442 0.7× 108 0.2× 102 0.2× 89 2.7k
Truyen Nguyen United States 17 393 0.4× 5.2k 7.1× 548 0.9× 333 0.6× 141 0.3× 19 6.9k
Walter C. Prozialeck United States 39 494 0.5× 1.4k 2.0× 890 1.5× 171 0.3× 49 0.1× 99 5.0k
Diane E. Heck United States 36 461 0.5× 1.5k 2.0× 239 0.4× 171 0.3× 63 0.2× 132 4.5k
Dale A. Dickinson United States 27 803 0.8× 1.9k 2.6× 280 0.5× 196 0.3× 41 0.1× 37 3.5k
Cecil B. Pickett United States 25 440 0.5× 6.0k 8.3× 575 0.9× 370 0.6× 152 0.4× 46 7.8k

Countries citing papers authored by Michael Rothe

Since Specialization
Citations

This map shows the geographic impact of Michael Rothe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Rothe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Rothe more than expected).

Fields of papers citing papers by Michael Rothe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Rothe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Rothe. The network helps show where Michael Rothe may publish in the future.

Co-authorship network of co-authors of Michael Rothe

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Rothe. A scholar is included among the top collaborators of Michael Rothe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Rothe. Michael Rothe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Stehling, Sabine, et al.. (2024). Eicosanoid biosynthesizing enzymes in Prototheria. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1870(1). 159569–159569.
2.
Flenkenthaler, Florian, Elisabeth Kemter, Mark Haid, et al.. (2024). Multi-omics analysis of diabetic pig lungs reveals molecular derangements underlying pulmonary complications of diabetes mellitus. Disease Models & Mechanisms. 17(7). 1 indexed citations
3.
Rothe, Michael, et al.. (2024). Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study. JCO Precision Oncology. 8(8). e2300615–e2300615. 1 indexed citations
4.
Tsvetkov, D, Johanna Schleifenbaum, Mario Kaßmann, et al.. (2023). KCNQ5 Controls Perivascular Adipose Tissue–Mediated Vasodilation. Hypertension. 81(3). 561–571. 4 indexed citations
5.
Ahn, Eugene R., Michael Rothe, Pam K. Mangat, et al.. (2023). Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study. JCO Precision Oncology. 7(7). e2200609–e2200609. 12 indexed citations
6.
7.
Srkalović, Gordan, Michael Rothe, Pam K. Mangat, et al.. (2023). Talazoparib (Tala) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. Journal of Clinical Oncology. 41(16_suppl). 3115–3115.
8.
Mileham, Kathryn F., Michael Rothe, Pam K. Mangat, et al.. (2023). Abstract CT226: Crizotinib (C) in patients (pts) with solid tumors with MET amplification (amp) or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Cancer Research. 83(8_Supplement). CT226–CT226. 1 indexed citations
9.
Ganti, Apar Kishor, Michael Rothe, Pam K. Mangat, et al.. (2023). Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology. 7(7). e2300041–e2300041. 6 indexed citations
10.
Liu, Tong, et al.. (2022). Hemodialysis and Plasma Oxylipin Biotransformation in Peripheral Tissue. Metabolites. 12(1). 34–34. 5 indexed citations
11.
Liu, Tong, et al.. (2022). Bioaccumulation of Blood Long-Chain Fatty Acids during Hemodialysis. Metabolites. 12(3). 269–269. 2 indexed citations
12.
Rothe, Michael, et al.. (2022). Hemodialysis and biotransformation of erythrocyte epoxy fatty acids in peripheral tissue. Prostaglandins Leukotrienes and Essential Fatty Acids. 181. 102453–102453. 2 indexed citations
13.
Rothe, Michael, et al.. (2020). Effects of hemodialysis on blood fatty acids. Physiological Reports. 8(2). e14332–e14332. 6 indexed citations
14.
Liu, Tong, et al.. (2020). Hemodialysis and erythrocyte epoxy fatty acids. Physiological Reports. 8(20). e14601–e14601. 3 indexed citations
15.
Rothe, Michael, et al.. (2020). Effects of hemodialysis on plasma oxylipins. Physiological Reports. 8(12). e14447–e14447. 7 indexed citations
16.
Rothe, Michael, et al.. (2019). Maximal exercise and erythrocyte epoxy fatty acids: a lipidomics study. Physiological Reports. 7(22). e14275–e14275. 10 indexed citations
17.
Rothe, Michael, et al.. (2019). Maximal exercise and plasma cytochrome P450 and lipoxygenase mediators: a lipidomics study. Physiological Reports. 7(13). e14165–e14165. 19 indexed citations
18.
Bonafini, Sara, Alice Giontella, Angela Tagetti, et al.. (2018). Possible Role of CYP450 Generated Omega-3/Omega-6 PUFA Metabolites in the Modulation of Blood Pressure and Vascular Function in Obese Children. Nutrients. 10(11). 1689–1689. 9 indexed citations
19.
Schmöcker, Christoph, et al.. (2016). A lipidomic analysis approach in patients undergoing lipoprotein apheresis. Atherosclerosis. 249. 30–35. 5 indexed citations
20.
Dengke, K., Michael Rothe, Shu Zheng, et al.. (2013). Cytochrome P450 Drives a HIF-Regulated Behavioral Response to Reoxygenation by C. elegans. Science. 341(6145). 554–558. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alberto Boveris Breakdown of academic impact, for papers by Jean Chaudière Breakdown of academic impact, for papers by Holger Steinbrenner Breakdown of academic impact, for papers by Yoshiaki Hashimoto Breakdown of academic impact, for papers by Desirée Bartolini Breakdown of academic impact, for papers by Truyen Nguyen Breakdown of academic impact, for papers by Walter C. Prozialeck Breakdown of academic impact, for papers by Diane E. Heck Breakdown of academic impact, for papers by Dale A. Dickinson Breakdown of academic impact, for papers by Cecil B. Pickett
Rankless by CCL
2026